scholarly journals Saudi Honey: A Promising Therapeutic Agent for Treating Wound Infections

Cureus ◽  
2021 ◽  
Author(s):  
Abdulrahman S Bazaid ◽  
Abdu Aldarhami ◽  
Hattan Gattan ◽  
Bakheet Aljuhani
Keyword(s):  
Therapeutic Agent ◽  
Wound Infections ◽  
Promising Therapeutic Agent

scholarly journals Therapeutic Management of a Substantial Pelvic Aneurysmatic Bone Cyst Including the Off-Label Use of Denosumab in a 35-Year-Old Female Patient

2017 ◽  
Vol 2017 ◽  
pp. 1-5
Author(s):  
D. Ntalos ◽  
M. Priemel ◽  
C. Schlickewei ◽  
D. M. Thiesen ◽  
J. M. Rueger ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Female Patient ◽  
Therapeutic Agent ◽  
Surgical Intervention ◽  
Case Reports ◽  
Bone Cyst ◽  
Off Label Use ◽  
Aneurysmal Bone Cysts ◽  
Promising Therapeutic Agent

Aneurysmal bone cysts (ABC) are benign bone tumors, which are highly vascularized. The main course of treatment is curettage followed by bone grafting or cement insertion. Still recurrence remains a main problem for patients. Denosumab is a monoclonal antibody, which acts as an inhibitor of the RANK/RANKL pathway, diminishing bone turnover. Recent case reports have shown that Denosumab can be a promising therapeutic agent for people suffering from therapy-resistant ABC. We report the case of a 35-year-old female patient presenting with a pronounced ABC of the pelvis. Since the tumor was inoperable, Denosumab was administered, leading to a significant shrinkage of the lesion, which allowed surgical intervention. Upon recurrence, Denosumab was restarted putting the patient once more into remission. Follow-up was four years overall with a clinical and radiological stable disease for fifteen months after final discontinuation of the monoclonal antibody. Therefore, our case further underlines the potential of Denosumab in the treatment of ABC.

scholarly journals Author Correction: A VCP modulator, KUS121, as a promising therapeutic agent for post-traumatic osteoarthritis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Motoo Saito ◽  
Kohei Nishitani ◽  
Hanako O. Ikeda ◽  
Shigeo Yoshida ◽  
Sachiko Iwai ◽  
...  
Keyword(s):  
Therapeutic Agent ◽  
Post Traumatic ◽  
Promising Therapeutic Agent

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

scholarly journals Neutrophil elastase inhibitor sivelestat ameliorates gefitinib-naphthalene-induced acute pneumonitis in mice

2017 ◽  
Author(s):  
Hironori Mikumo ◽  
Toyoshi Yanagihara ◽  
Naoki Hamada ◽  
Eiji Harada ◽  
Saiko Ogata-Suetsugu ◽  
...  
Keyword(s):  
Neutrophil Elastase ◽  
Therapeutic Agent ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Lavage Fluid ◽  
Egfr Mutations ◽  
Airway Epithelial ◽  
Neutrophil Elastase Inhibitor ◽  
Elastase Inhibitor ◽  
Promising Therapeutic Agent

ABSTRACTBackground and objectiveGefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is an effective therapeutic agent for non-small cell lung cancer with EGFR mutations. It can cause severe acute pneumonitis in some patients. We previously demonstrated that mice with naphthalene-induced airway epithelial injury developed severe gefitinib-induced pneumonitis and that neutrophils played important roles in the development of the disease. This study aimed to investigate the effects of the neutrophil elastase inhibitor sivelestat on gefitinib-induced pneumonitis in mice.MethodsC57BL/6J mice received naphthalene (200 mg/kg) intraperitoneally on day 0. Gefitinib (250 or 300 mg/kg) was orally administered to mice from day −1 until day 13. Sivelestat (150 mg/kg) was administered intraperitoneally from day 1 until day 13. Bronchoalveolar lavage fluid (BALF) and lung tissues were sampled on day 14.ResultsSivelestat treatment significantly reduced the protein level, neutrophil count, neutrophil elastase activity in BALF, and severity of histopathologic findings on day 14 for mice administered with 250 mg/kg of gefitinib. Moreover, sivelestat treatment significantly improved the survival of mice administered with 300 mg/kg of gefitinib. Conclusions: These results indicate that sivelestat is a promising therapeutic agent for severe acute pneumonitis caused by gefitinib.Summary statementNeutrophil elastase inhibitor sivelestat is a promising therapeutic agent for severe acute pneumonitis caused by gefitinib.

scholarly journals Past, Present and Future of Oncolytic Reovirus

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3219
Author(s):  
Louise Müller ◽  
Robert Berkeley ◽  
Tyler Barr ◽  
Elizabeth Ilett ◽  
Fiona Errington-Mais
Keyword(s):  
Immune Responses ◽  
Therapeutic Agent ◽  
Tumour Microenvironment ◽  
Oncolytic Viruses ◽  
Full Potential ◽  
Cellular Mechanisms ◽  
Tumour Immunity ◽  
Combination Strategies ◽  
Significant Attention ◽  
Promising Therapeutic Agent

Oncolytic virotherapy (OVT) has received significant attention in recent years, especially since the approval of talimogene Laherparepvec (T-VEC) in 2015 by the Food and Drug administration (FDA). Mechanistic studies of oncolytic viruses (OVs) have revealed that most, if not all, OVs induce direct oncolysis and stimulate innate and adaptive anti-tumour immunity. With the advancement of tumour modelling, allowing characterisation of the effects of tumour microenvironment (TME) components and identification of the cellular mechanisms required for cell death (both direct oncolysis and anti-tumour immune responses), it is clear that a “one size fits all” approach is not applicable to all OVs, or indeed the same OV across different tumour types and disease locations. This article will provide an unbiased review of oncolytic reovirus (clinically formulated as pelareorep), including the molecular and cellular requirements for reovirus oncolysis and anti-tumour immunity, reports of pre-clinical efficacy and its overall clinical trajectory. Moreover, as it is now abundantly clear that the true potential of all OVs, including reovirus, will only be reached upon the development of synergistic combination strategies, reovirus combination therapeutics will be discussed, including the limitations and challenges that remain to harness the full potential of this promising therapeutic agent.

scholarly journals CEREBROPROTEIN HYDROLYSATE INDUCED SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS): A CASE REPORT

2016 ◽  
Vol 9 (1) ◽  
pp. 321 ◽  
Author(s):  
Tarali Devi ◽  
Subhash Sarma ◽  
Urmi Choudhury
Keyword(s):  
Traumatic Brain Injury ◽  
Case Report ◽  
Side Effects ◽  
Systemic Inflammatory Response Syndrome ◽  
Inflammatory Response ◽  
Ischaemic Stroke ◽  
Acute Ischaemic Stroke ◽  
Therapeutic Agent ◽  
Systemic Inflammatory Response ◽  
Promising Therapeutic Agent

<p>Cerebroprotein hydrolysate is a newer pharmacological neurotropic agent and considered as a promising therapeutic agent for dementia, Alzheimer’s disease, traumatic brain injury and acute ischaemic stroke. Studies revealed that most of the side effects are minor. Here, we reported a case of Systemic inflammatory response syndrome (SIRS) probably due to use of Cerebroprotein hydrolysate in a patient with acute ischaemic stroke.</p>

scholarly journals Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges

Nanomaterials ◽  
2019 ◽  
Vol 9 (12) ◽  
pp. 1749 ◽  
Author(s):  
Kiran Saleem ◽  
Zainab Khursheed ◽  
Christophe Hano ◽  
Iram Anjum ◽  
Sumaira Anjum
Keyword(s):  
Targeted Drug Delivery ◽  
Targeted Delivery ◽  
Liposomal Amphotericin ◽  
Therapeutic Agent ◽  
Polymeric Nanoparticles ◽  
Chemotherapeutic Drugs ◽  
Metallic Oxide ◽  
Disease Treatment ◽  
Targeted Drug ◽  
Promising Therapeutic Agent

Leishmaniasis is a widely distributed protozoan vector-born disease affecting almost 350 million people. Initially, chemotherapeutic drugs were employed for leishmania treatment but they had toxic side effects. Various nanotechnology-based techniques and products have emerged as anti-leishmanial drugs, including liposomes, lipid nano-capsules, metal and metallic oxide nanoparticles, polymeric nanoparticles, nanotubes and nanovaccines, due to their unique properties, such as bioavailability, lowered toxicity, targeted drug delivery, and biodegradability. Many new studies have emerged with nanoparticles serving as promising therapeutic agent for anti-leishmanial disease treatment. Liposomal Amphotericin B (AmB) is one of the successful nano-based drugs with high efficacy and negligible toxicity. A new nanovaccine concept has been studied as a carrier for targeted delivery. This review discusses different nanotechnology-based techniques, materials, and their efficacies in leishmaniasis treatment and their futuristic improvements.

3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells

2011 ◽  
Vol 130 (11) ◽  
pp. 2557-2567 ◽  
Author(s):  
Tetsuhiro Chiba ◽  
Eiichiro Suzuki ◽  
Masamitsu Negishi ◽  
Atsunori Saraya ◽  
Satoru Miyagi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Therapeutic Agent ◽  
Carcinoma Cells ◽  
Hepatocellular Carcinoma Cells ◽  
Promising Therapeutic Agent
Sign in / Sign up

Export Citation Format

Share Document